Valion Bio’s Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone

Velocity Bioworks successfully completes initial evaluation of LarmorBio’s BioScan-NMR™ platform, generating data supporting the continued development of continuous, real-time, non-invasive bioprocess monitoring of cell size, density, viability, and phenotype within bioreactors

Milestone achieved less than six months after Valion Bio secured exclusive rights to LarmorBio’s next-generation NMR technology

SAN ANTONIO, TX AND WALTHAM, MA / ACCESS Newswire / October 15, 2026 / Valion Bio, Inc. (NASDAQ:VBIO)